Nothing in the current IB structure changes – the programme just builds on it. Partners earn through two independent revenue streams: IB commissions from brokers and affiliate commissions from cTrader ...

Neumora Therapeutics Inc (NMRA) showcases promising clinical developments and a robust cash runway, despite facing setbacks in toxicology studies.

The IB ACIO recruitment process has reached its final stage following the declaration of the Tier 2 result on March 5, 2026.

With enpatoran soon entering Phase III clinical trials, the Phase II safety and efficacy results support the drug’s development.

Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid Margrave ...

Research and development expenses excluding the share-based payment expenses were RMB299.5 million for the year ended ...

If you think a student’s success is measured solely by the grade point average on their academic transcript, you might need ...

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales ...

Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford. Earlier today, Rani released financial ...

Novo Nordisk NVO and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line ...

Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript March 25, 2026 Celcuity Inc. beats earnings expectations. Reported EPS is $-0.97, expectations were $-1.06. Operator: Good afternoon, ...

Celcuity’s latest earnings call struck a notably optimistic tone, as management emphasized powerful Phase III results, a fast-track regulatory path and solid funding that could carry the company into ...